Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19975472 | 1.00 | MAPK1 (0.40) | MAPK1ALDH1A1LMNAESR1KMT2A | |
| SCHEMBL21183534 | 1.00 | MAPK1 (0.40) | MAPK1ALDH1A1LMNAESR1KMT2A | |
| SCHEMBL21183522 | 0.89 | L3MBTL1 (0.46) | MAPK1ALDH1A1LMNAESR1KMT2A | |
| SCHEMBL19974888 | 0.87 | L3MBTL1 (0.36) | MAPK1ALDH1A1LMNAESR1KMT2A | |
| SCHEMBL19975449 | 0.87 | L3MBTL1 (0.36) | MAPK1ALDH1A1LMNAESR1KMT2A | |
| SCHEMBL19974891 | 0.87 | L3MBTL1 (0.36) | MAPK1ALDH1A1LMNAESR1KMT2A | |
| SCHEMBL19975358 | 0.84 | POLB (0.45) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL19975357 | 0.84 | POLB (0.45) | ALDH1A1LMNAKMT2AMEN1POLB | |
| SCHEMBL19975096 | 0.83 | HPGD (0.47) | MAPK1ALDH1A1ESR1KMT2AMEN1 | |
| SCHEMBL19975494 | 0.83 | CYP1A2 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | MAPK1 3870/4885ALDH1A1 2271/4885LMNA 1909/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | MAPK1 4083/4885ALDH1A1 2673/4885LMNA 2058/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | MAPK1 3870/4885ALDH1A1 2271/4885LMNA 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.